Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723522 | 0.94 | GLA (0.73) | GLATSHRTYMPGPR84ALDH1A1 | |
| SCHEMBL10396476 | 0.78 | GLA (0.47) | GLAPARP1ALDH1A1MAPK1HCAR3 | |
| SCHEMBL4049125 | 0.78 | GLA (0.57) | GLATSHRDAO | |
| SCHEMBL9414255 | 0.75 | PARP1 (0.46) | GLAPARP1TYMPGPR84ALDH1A1 | |
| SCHEMBL16852654 | 0.72 | GLA (0.61) | GLATSHRDAOALDH1A1MAPK1 | |
| SCHEMBL9414226 | 0.72 | PARP1 (0.44) | GLAPARP1TYMPGPR84ALDH1A1 | |
| SCHEMBL6685725 | 0.69 | GPR84 (0.51) | GLATYMPGPR84ALDH1A1 | |
| SCHEMBL251649 | 0.69 | TYMP (0.47) | GLATSHRTYMPGPR84ALDH1A1 | |
| SCHEMBL13307385 | 0.69 | GLA (0.57) | GLATSHRALDH1A1 | |
| SCHEMBL7325204 | 0.68 | MAPT (0.41) | GLATSHRPARP1TYMPGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018077944-A2 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
| CN-102333779-B | Benzopyran and benzoxex PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-09 | — | — | CN | disclosed |
| EP-2343980-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Wu, Nian (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010027496-A1 | TRIAZOLE ANTIFUNGAL AGENTS | WU NIAN (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | NR3C2, AGTR1, PAH | GLA 4674/4885TSHR 745/4885PARP1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.